Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May;19(5):286.
doi: 10.1038/s41569-022-00693-x.

Benefit of empagliflozin in acute heart failure

Gregory B Lim  1
Affiliations
Comment

Benefit of empagliflozin in acute heart failure

Gregory B Lim. Nat Rev Cardiol. 2022 May.
No abstract available

PubMed Disclaimer

Comment on

  • The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
    Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. Voors AA, et al. Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228754 Free PMC article. Clinical Trial.

References

Original article
    1. Voors, A. A. et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat. Med. https://doi.org/10.1038/s41591-021-01659-1 (2022) - DOI - PubMed - PMC

LinkOut - more resources